|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In women aged 25-49 years, the annualized cancer incidence was 1.6% in BRCA1, 1.4% in BRCA2 mutation carriers, and 0.5% in noncarriers.
|
31657879 |
2020 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here, we show that fork degradation is no longer detectable in BRCA1-deficient cancer cells exposed to multiple cisplatin doses, mimicking a clinical treatment regimen.
|
31676232 |
2020 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In addition, the levels and patterns of ADPRylation, PARP-1 protein, and gene expression correlated with clinical outcomes in response to platinum-based chemotherapy, with cancers exhibiting the highest levels of ADPRylation having the best outcomes independent of BRCA1/2 status.
|
31594824 |
2020 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We irradiated HT1080, M059K (DNA-PKcs<sup>+/+</sup>), and HCC1937 human cancer cell lines and their isogenic counterparts HT1080-shDNA-PKcs, HT1080-shRAD51<sup>IND</sup>, M059J (DNA-PKcs<sup>-/-</sup>), and HCC1937-BRCA1 (BRCA1 complemented) to assess cell clonogenic survival and γ-H2AX radiation-induced foci.
|
31425731 |
2019 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We found that four E3 ubiquitin ligases (UHRF1, BRCA1, TRAIP and HLTF) and one regulator of ubiquitin E3 activity DCUN1D1 that were dramatically up-regulated in cancer were significantly associated with tumor metastasis and patient's poor prognosis both in two transcriptome data sets.
|
30528265 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Moreover, MCL1 inhibition potentiates the in vivo efficacy of PARP inhibition (PARPi), underscoring the therapeutic potential of this combination for treatment of BRCA1-mutated cancer patients with poor response to PARPi monotherapy.
|
30674894 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
|
30551077 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to compare patient-reported outcomes (PROs) of BRCA1/2 mutation carriers, either after bilateral prophylactic mastectomy (BPM) or during breast surveillance, to improve shared decision-making in their cancer risk management.
|
31832891 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
This method is useful for identifying BRCA1 deficiencies and localization in a variety of research fields, including development, neurodegeneration, and cancer.
|
31069686 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A total of 54 (23.3%) ovarian cancer patients were found to harbor BRCA1/2 deleterious mutations, and BRCA1/2 mutations were significantly associated with Hereditary Breast and Ovarian Cancer-related tumors and family history of cancer.
|
30972954 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Therefore, using two large series of publicly available breast cancer datasets, namely that from The Cancer Genome Atlas and Wellcome Trust Institute, we sought to investigate the association between BRCA1- and BRCA2-deficiency with features of genomic instability, expression of PD-L1 and PD-1, landscape of inferred tumour-infiltrating immune cells, and T-cell inflamed signature in breast cancers.
|
31022191 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Despite calls for BRCA1/2 population screening, there remains a critical need to identify those most at risk who should receive cancer genetics services.
|
29740170 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The provision of genetic testing to high-risk women with a BRCA1 and two mutation probability of ≥ 10% based on the individual family cancer history appears to be a cost-effective option for the SHI.
|
30790097 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We have found that BRCA1, a multifunctional protein involved in DNA repair and epigenetic regulation, plays a critical role in the regulation of cancer stem cell (CSC)-like characteristics.
|
31273285 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
KEY POINTS: Germline mutations detected in pediatric gliomas may represent a cancer predisposition syndrome.Integrating molecular testing into routine clinical care for pediatric patients with glioma is critical to identify therapeutic targets and patients with a cancer predisposition syndrome.Patients with glioma with defects in DNA repair pathway components (e.g., <i>BRCA1/2</i>) may show increased responsiveness to poly (ADP-ribose) polymerase (PARP) inhibitors.Combining PARP inhibitors with temozolomide (standard-of-care treatment) revealed no adverse events or toxicities over the course of 18 months.
|
31619547 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Intriguingly, in specimens with BRCA1 mutations known to predispose for cancer, higher frequencies of lobular vDP cells are observed.
|
31619692 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.
|
30694012 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These data may have implications for risk assessment and cancer prevention decision making for carriers of the BRCA1 duplication exon 13 mutation.
|
30136106 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Therapeutic strategies designed to tinker with cancer cell DNA damage response have led to the widespread use of PARP inhibitors for BRCA1/2-mutated cancers.
|
31727767 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Among the 481 female patients, 135 patients were detected to carry pathogenic (P)/likely pathogenic (LP) mutations (28.1%), which corresponded to 12 different cancer predisposition genes [14.6% (70/481) on BRCA1 gene, 5.0% (24/481) on BRCA2 gene, 8.5% (41/481) on non-BRCA1/2 genes].
|
30982232 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Factors that predicted for BRCA1/2 mutations were: breast and ovarian cancers in the same patient (p = 0.031), young age of EOC (p = 0.029), menstrual status (p = 0.004) and family history of cancer (p < 0.0001).
|
30651582 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers.
|
31112363 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We identify genetic variants of BRCA1-BARD1 in patients with cancer that exhibit poor protection of nascent strands but retain homologous recombination proficiency, thus defining domains of BRCA1-BARD1 that are required for fork protection and associated with cancer development.
|
31270457 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We recommend BRCA1/2 testing for patients with family histories and personal histories of malignancy and genetic counseling for cancer in healthy people with high-risk family histories.
|
31411802 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Biallelic BRCA1 mutations are regarded either embryonically lethal or to cause Fanconi anemia (FA), a genomic instability syndrome characterized by bone marrow failure, developmental abnormalities, and cancer predisposition.
|
31347298 |
2019 |